Content about India

April 7, 2014

Sun Pharma on Sunday announced it will acquire 100% of Ranbaxy in an all-stock transaction valued at $4 billion.

MUMBAI, India — Sun Pharma on Sunday announced it will acquire 100% of Ranbaxy in an all-stock transaction valued at $4 billion. 

The combination of Sun Pharma and Ranbaxy creates the fifth-largest specialty generics company in the world and the largest pharmaceutical company in India, Sun Pharma stated. The combined entity will have operations in 65 countries, 47 manufacturing facilities across five continents, and a significant platform of specialty and generic products marketed globally, including 629 abbreviated new drug applications. 

March 28, 2014

Dr. Reddy's Labs announced that it has launched amlodipine besylate and atorvastatin calcium tablets, a generic version of Caduet.

HYDERABAD, India — Dr. Reddy's Labs announced that it has launched amlodipine besylate and atorvastatin calcium tablets, a generic version of Caduet.

The Caduet tablets brand and generic had sales in the United States of approximately $163 million MAT for the most recent 12 months ended January 2014, according to IMS Health.

March 10, 2014

Although the United States is still waiting for final practical guidelines from the Food and Drug Administration about the launch of biosimilars and the standards required to meet the threshold of interchangeability, the rest of the world seems to be barreling forward with the development and launch of these important medicines.

Although the United States is still waiting for final practical guidelines from the Food and Drug Administration about the launch of biosimilars and the standards required to meet the threshold of interchangeability, the rest of the world seems to be barreling forward with the development and launch of these important medicines. By the end of this decade, a significant number of blockbuster drugs will go off patent, paving the way for biosimlar market entrance.

March 5, 2014

Dr. Reddy's Labs announced the launch of moxifloxacin hydrochloride tablets — the generic version of Avelox tablets — in 400-mg form.

HYDERABAD, India — Dr. Reddy's Labs announced the launch of moxifloxacin hydrochloride tablets, the generic version of Avelox tablets, in 400-mg form. The drug is available in bottle counts of 30.

Avelox tablets had U.S. sales of approximately $195 million for the 12 months ending in December 2013, according to IMS Health.

 

February 26, 2014

Dr. Reddy's Labs announced that it has launched Sumatriptan Injection USP, Autoinjector System 6-mg/0.5-mL, a generic version of Imitrex STATdose Pen (sumatriptan succinate) 6-mg/0.5-mL.

HYDERABAD, India — Dr. Reddy's Labs announced that it has launched Sumatriptan Injection USP, Autoinjector System 6-mg/0.5-mL, a generic version of Imitrex STATdose Pen (sumatriptan succinate) 6-mg/0.5-mL. The drug is available in a carton containing 2 single-dose prefilled syringes.

Sumatriptan is used to treat acute migraine headaches with or without aura and acute cluster headaches in adults who have been diagnosed with migraine or cluster headaches, according to the company.

February 3, 2014

Mylan on Monday announced that its subsidiary has launched the world's first trastuzumab biosimilar in India, which will be marketed by Mylan as Hertraz.

MUMBAI and PITTSBURGH — Mylan on Monday announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched the world's first trastuzumab biosimilar in India. The product — which will be marketed by Mylan as Hertraz — is used for the treatment of HER2-positive metastatic breast cancer. Hertraz is a biosimilar to Roche's Herceptin and is available in two strengths:  440mg and 150mg.

January 31, 2014

Mylan announced that its India-based subsidiary, Mylan Pharmaceuticals Private Limited, has been named Gilead Sciences' branded medicines business partner for India.

PITTSBURGH and MUMBAI, India — Mylan announced that its India-based subsidiary, Mylan Pharmaceuticals Private Limited, has been named Gilead Sciences' branded medicines business partner for India.

Under this exclusive agreement, Mylan will market and distribute in India the following drugs from Gilead:

January 21, 2014

Actavis Pharma recently announced that it intends to enter into an agreement for Aurobindo Pharma to acquire Actavis' generics commercial operations in seven markets in Western Europe.

DUBLIN — Actavis Pharma recently announced that it intends to enter into an agreement for Aurobindo Pharma to acquire Actavis' generics commercial operations in seven markets in Western Europe. The transaction is conditional on certain antitrust approvals and completion of employee consultation processes. 

January 21, 2014

The Estée Lauder Cos. has announced the promotion of Chris Good to president, United Kingdom and Ireland, and Sandra Main to global brand president, La Mer.

NEW YORK — The Estée Lauder Cos. has announced the promotion of Chris Good to president, United Kingdom and Ireland, and Sandra Main to global brand president, La Mer.

January 13, 2014

The Food and Drug Administration has found possible violations of agency regulations at a manufacturing plant in India owned by drug maker Ranbaxy Labs, the company said Monday.

GURGAON, India — The Food and Drug Administration has found possible violations of agency regulations at a manufacturing plant in India owned by drug maker Ranbaxy Labs, the company said Monday.

Ranbaxy said it received a Form 483 from the FDA, a statement issued to a company's management after it has inspected a plant and found conditions that may violate the agency's regulations, and that products produced therein could be hazardous to people who use them. The plant in question is in Toansa, in India's Punjab region.

January 2, 2014

Mylan has hired Rakesh Bamzai as its president for commercial and emerging markets in India, the drug maker said.

PITTSBURGH — Mylan has hired Rakesh Bamzai as its president for commercial and emerging markets in India, the drug maker said Thursday.

Mylan said Bamzai has more than 20 years of experience in the drug industry, having previously served as president of marketing at Biocon.

December 2, 2013

The Food and Drug Administration has approved a generic version of a drug for schizophrenia and bipolar disorder made by Jubilant Life Sciences, the Indian drug maker said.

NOIDA, India — The Food and Drug Administration has approved a generic version of a drug for schizophrenia and bipolar disorder made by Jubilant Life Sciences, the Indian drug maker said.

Jubilant announced the approval of quetiapine fumarate tablets in the 25-mg strength. The drug is a generic version of AstraZeneca's Seroquel.

Various versions of the drug have annual sales of about $59 million, according to IMS Health.

 

November 20, 2013

Ranbaxy Labs is celebrating the 20th anniversary of its operations in Ukraine, the Indian generic drug maker said Wednesday.

GURGAON, India — Ranbaxy Labs is celebrating the 20th anniversary of its operations in Ukraine, the Indian generic drug maker said Wednesday.

The drug maker established a base in the eastern European country in 1993 and has since become the largest drug company in the market, whose value is estimated at $3.7 billion, according to the company. Ranbaxy's products in Ukraine include branded and generic drugs.

November 6, 2013

Many physicians in Asia say more information on managing Type 2 diabetes is needed, according to a new poll.

INDIANAPOLIS — Many physicians in Asia say more information on managing Type 2 diabetes is needed, according to a new poll.

November 1, 2013

Indian drug maker Dr. Reddy's Labs had sales of $536 million in second quarter 2014 and profits of $110 million, the company said.

HYDERABAD, India — Indian drug maker Dr. Reddy's Labs had sales of $536 million in second-quarter 2014 and profits of $110 million, the company said.

Those figures represented sales growth of 17% and a 76% growth in profits over second quarter 2013. Seventy-nine percent of the company's sales came from generic drugs, including 50% from sales in North America; sales of generics grew by 32% over last year.

October 29, 2013

Ranbaxy Labs had global sales of $447.6 million in third quarter 2013, compared with $434.6 million in third quarter 2012, the Indian drug maker said Tuesday.

GURGAON, India — Ranbaxy Labs had global sales of $447.6 million in third quarter 2013, compared with $434.6 million in third quarter 2012, the Indian drug maker said Tuesday.

Sales from generics were $208.4 million, while branded and OTC drugs had sales of $239.3 million North American sales were $143.24 million including $128.6 million in the United States, lower than in Q3 2012 due to a large contribution last year from new generic drugs.

October 22, 2013

The Food and Drug Administration has approved drugs for depression and smoking cessation made by Jubilant Life Sciences, the company said.

NOIDA, India — The Food and Drug Administration has approved drugs for depression and smoking cessation made by Jubilant Life Sciences, the company said.

Jubilant, based in India, announced the approval of generic bupropion hydrochloride extended-release tablets in the 100-mg, 150-mg and 200-mg strengths, and another bupropion hydrochloride extended-release tablet product in the 150-mg strength.

The first product is a generic version of GlaxoSmithKline's antidepressant Wellbutrin SR, while the second is a version of GSK's anti-smoking drug Zyban.

September 17, 2013

The Food and Drug Administration has approved an injected drug for the bone marrow disorder myelodysplastic syndrome made by Dr. Reddy's Labs, the company said Tuesday.

HYDERABAD, India — The Food and Drug Administration has approved an injected drug for the bone marrow disorder myelodysplastic syndrome made by Dr. Reddy's Labs, the company said Tuesday.

Dr. Reddy's announced the approval of azacitidine injection in the 100-mg-per-vial strength. The drug is a generic version of Celgene's Vidaza, and Dr. Reddy's plans to launch the product in the near future.

Vidaza had sales of about $378.5 million during the 12-month period ended in July, according to IMS Health.

 

September 16, 2013

The Food and Drug Administration has approved a drug made by Sun Pharmaceutical Industries for ulcers, Sun said.

MUMBAI, India — The Food and Drug Administration has approved a drug made by Sun Pharmaceutical Industries for ulcers, Sun said.

Sun announced the approval of lansoprazole delayed-release capsules in the 15-mg and 30-mg strengths.

The drug is a generic version of Takeda's Prevacid delayed-release capsules, which are used for treatment lasting up to four weeks for healing and symptom relief of active duodenal ulcers.

Various versions of the drug have annual sales of about $430 million per year, according to Sun.

 

September 16, 2013

The Food and Drug Administration is barring the importation of drugs from another one of Ranbaxy Labs' plants in India, the agency said Monday.

SILVER SPRING, Md. – The Food and Drug Administration is barring the importation of drugs from another one of Ranbaxy Labs' plants in India, the agency said Monday.

September 10, 2013

Ranbaxy Labs recently marked the 20th anniversary of its operations in Russia, the India-based generic drug company announced.

GURGAON, India — Ranbaxy Labs recently marked the 20th anniversary of its operations in Russia, the India-based generic drug company announced.

Ranbaxy established its operations in the Russian market in 1993 with the launch of its key brand, Cifran, and since then, it has grown to command a market share of 15.4% in the country, according to IMS Health.

August 23, 2013

Indian drug maker Dr. Reddy's Labs has launched a generic treatment for epilepsy, the company said.

HYDERABAD, India — Indian drug maker Dr. Reddy's Labs has launched a generic treatment for epilepsy, the company said.

Dr. Reddy's announced the launch of divalproex sodium extended-release tablets in the 250-mg and 500-mg strengths, used to treat epileptic seizures. The 250-mg tablets are available in bottle count sizes of 100, while the 500-mg tablets are available in sizes of 100 and 500.

July 29, 2013

Dr. Reddy's Labs has launched a generic drug used to treat Alzheimer's disease, the company said.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic drug used to treat Alzheimer's disease, the company said.

The Indian drug maker announced the launch of donepezil hydrochloride tablets in the 23-mg strength, a generic version of Eisai and Pfizer's Aricept. The drug is being launched in 30- and 90-count bottles.

Aricept in the 23-mg strength had sales of about $92.6 million during the 12-month period that ended in May, according to IMS Health.

 

July 23, 2013

The Food and Drug Administration has approved a generic diabetes drug made by Lupin, the company said.

MUMBAI, India — The Food and Drug Administration has approved a generic diabetes drug made by Lupin, the company said.

Lupin, based in India, received approval for metformin hydrochloride extended-release tablets in the 500-mg and 1,000-mg strengths. The drug is a generic version of Santarus' Glumetza.

Glumetza had sales of about $144 million during the 12-month period that ended in March, according to IMS Health. The drug is an extended-release formulation of metformin hydrochloride, a widely prescribed drug used for treating Type 2 diabetes.

 

July 12, 2013

The Indian generic drug maker announced the approval of repaglinide tablets in the 1-mg and 2-mg strengths, which are used in combination with diet and exercise to improve blood-sugar control in patients with Type 2 diabetes.

MUMBAI, India — The Food and Drug Administration has approved a generic diabetes drug made by Sun Pharmaceutical Industries, Sun said Friday.

The Indian generic drug maker announced the approval of repaglinide tablets in the 1-mg and 2-mg strengths, which are used in combination with diet and exercise to improve blood-sugar control in patients with Type 2 diabetes.